Company intelligence / Profile preview

Nerio Therapeutics

La Jolla, California, United Statesvivabioinnovator.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Nerio developed first-in-class small molecule inhibitors of PTPN1/2, showing robust anti-tumor activity and immune activation in preclinical models. The lead program was preparing for IND submission before the company was acquired by Boehringer Ingelheim for up to $1.3 billion to become a centerpiece of their immuno-oncology pipeline.[3][4][5][6]

Therapeutic areas: Oncology
Modalities: Small molecules (specifically allosteric/uncompetitive inhibitors)[1][2]
Industry: Biotech

Partnerships

Avalon BioVentures accelerator/incubator support[5]

Beyond the preview

Go deeper on Nerio Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nerio Therapeutics.

Explore the full profile